INmune Bio Inc. (INMB) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you. Welcome to InMuneBio's second quarter 2026 earnings call. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question and answer session, at which time you may press star one to ask a question. As a reminder, this conference call is being recorded. A transcript will be available approximately 24 hours after the call. Before we begin, Please note that except for statements of historical fact, statements made by management and responses to questions may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Please review the forward-looking statements disclaimer in today's earnings release and the risk factors described in the company's filings with the SEC, including its most recent quarterly report. Forward-looking statements speak only as of the date they are made and exempt as required by law. Immune Bio undertakes no obligation to update them. It is now my pleasure to turn the call over to Immune Bio's Chief Executive Officer, David Moss. Thank you for joining Immune Bio's second quarter conference call. The second quarter and the weeks that followed were defined by execution across both of our late stage platforms. I will begin with the investor perspective on the progress we have made. I will then turn the call over to Dr. Mark Lowdell, our Chief Scientific Officer and the inventor of Chordstrom to discuss Ebstracell and the Chordstrom platform in greater detail. Cory Ellspermann will review our financial results and I will return to discuss the milestones ahead before we open the ...